SAN DIEGO, California, July 1, 2019 – Neurana Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the appointment of Thomas Yonker, MBA Executive Director, Program Management.
Tom was previously Vice President of Program Management at PaxVax. Neurana is led by Craig Thompson, President & Chief Executive Officer and Kathy Scott, Chief Financial Officer. Neurana is privately held and funded by Soffinova Investment, Longitude Capital, New Leaf Venture Partners and Hale Biopharma Ventures.